Obesity: Low-Dose Orlistat Effects on Body Weight of Mildly to Moderately Overweight Individuals: A 16 Week, Double-Blind, Placebo-Controlled Trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Lifestyle measures are considered the first line of therapy for treating overweight individuals, but many are unable to achieve a meaningful weight loss. Objective: To determine the efficacy and safety of orlistat 60 mg, given 3 times daily, for weight loss in mildly to moderately overweight individuals. Methods: A multicenter, 16 week, randomized, double-blind, placebo-controlled study was conducted in 391 overweight subjects at 20 US centers. The main outcome measure was change in weight from baseline to week 16; secondary measures included changes in body mass index, waist circumference, blood pressure, and fasting lipoprotein and glucose levels. Results: Subjects in both groups lost weight over the treatment period; however, orlistat-treated subjects lost significantly more weight than placebo-treated subjects beyond 2 weeks of treatment. Weight loss from baseline to week 16 was significantly greater in participants receiving orlistat versus those receiving placebo (3.05 vs 1.90 kg; p < 0.001, intent-to-treat analysis). Orlistat-treated subjects who completed 16 weeks of treatment lost 4.8 ± 0.35% (mean ± SE) of baseline weight compared with 3.1 ± 0.38% for the placebo group (p < 0.001). Orlistat-treated subjects, compared with those receiving placebo, also demonstrated a greater relative reduction in total (–4.4% vs 0.0%; p = 0.004) and low-density lipoprotein cholesterol (–7.2% vs -0.6%; p = 0.005) and both diastolic (-3.9% vs -0.5%; p = 0.001) and systolic blood pressure (-4.7% vs -1.8%; p = 0.004). Both groups showed a similar safety profile; gastrointestinal events were significantly more common in the orlistat-treated subjects. Conclusions: The use of orlistat 60 mg by mildly to moderately overweight individuals produced significant weight loss in conjunction with a reduced calorie diet and self-instructional materials. This amount of weight loss was associated with improvements in several weight-related risk factors. Orlistat 60 mg may be a useful adjunct to lifestyle measures and has the potential to contribute significantly to weight and risk factor improvement for overweight individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
The worldwide obesity epidemic
James, P. T., Leach, R., Kalamara, E., & Shayeghi, M. (2001) · Obesity Research · doi:10.1038/oby.2001.123 · Cited by 1,201
Weight, Weight Change, and Coronary Heart Disease in Women: Risk Within the 'Normal' Weight Range
Willett, W. C. (1995) · JAMA · doi:10.1001/jama.1995.03520300035033 · Cited by 924
Obesity Accelerates the Progression of Coronary Atherosclerosis in Young Men
McGill, H. C., McMahan, C. A., Herderick, E. E., Zieske, A. W., Malcom, G. T., Tracy, R. E., & Strong, J. P. (2002) · Circulation · doi:10.1161/01.cir.0000018121.67607.ce · Cited by 684
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384
Orlistat in the long-term treatment of obesity in primary care settings.
Hauptman, J. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.2.160 · Cited by 367
Self-citation
Cited by
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
A review of current guidelines for the treatment of obesity
(2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89292 · Cited by 207
Zhou, Y.-H., Ma, X.-Q., Wu, C., Lu, J., Zhang, S.-S., Guo, J., Wu, S.-Q., Ye, X.-F., Xu, J.-F., & He, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039062 · Cited by 84
Smith, S. R., Stenlof, K. S., Greenway, F. L., McHutchison, J., Schwartz, S. M., Dev, V. B., Berk, E. S., & Kapikian, R. (2011) · Obesity · doi:10.1038/oby.2011.143 · Cited by 51
Self-citationChong, P., Beah, Z., Grube, B., & Riede, L. (2014) · Phytotherapy Research · doi:10.1002/ptr.5158 · Cited by 32
Metadata
- Authors
- Anderson, J. W., Schwartz, S. M., Hauptman, J., Boldrin, M., Rossi, M., Bansal, V., & Hale, C. A.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2006-10
- Volume
- 40
- Issue
- 10
- Pages
- 1717-1723
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2144712307
- Cited by
- 51
- References
- 8
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.